Processa Pharmaceuticals, Inc.

PCSA

$2.05

-2.38%

N/A-$0.05

Healthcare

Biotechnology

NASDAQ

활발히 거래 중

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with ...

PCSA 기초 분석

핵심 강점

Multi-asset pipeline spanning dermatology, GI disorders, and oncology, which diversifies clinical-stage event risk across indications

Lead program (PCS499) is in Phase 2B for necrobiosis lipoidica, offering a closer-to-value inflection point than earlier-stage assets

위험 요인

Pre-revenue, clinical-stage nature: value depends heavily on trial outcomes, making returns highly binary and sensitive to interim/final efficacy results

Liquidity and funding risk: current ratio and quick ratio are below 1 (≈0.866) with negative working capital and strongly negative free cash flow, increasing reliance on future capital raises

수익성

순이익률0.00%

영업이익률0.00%

밸류에이션

P/E 비율-0.37x

유동비율0.87

효율성

ROE-394.24%

ROA-649.33%

기초 분석 의 PCSA

Processa Pharmaceuticals (PCSA) is a clinical-stage biotechnology company with no commercial products to date, so its fundamentals are dominated by research execution, trial outcomes, and the availability/cost of capital rather than by current earnings power. The provided TTM snapshot shows weak/invalid standard profitability signals: net margin, gross margin, operating margin, and EBITDA/EBIT margins are effectively 0 in the dataset, and return metrics are negative on assets/equity (ROA/ROE approximately -6% to -4%), consistent with ongoing investment and likely net losses. Valuation ratios also appear non-meaningful: trailing P/E is negative (data-driven by losses), price-to-sales is 0 in the snapshot, and price-to-book is deeply negative, which typically occurs when book value is negative or very small. Liquidity is mixed: the current ratio is below 1 (0.866) and the quick ratio is 0.866, indicating limited near-term cushion and reliance on ongoing financing or cash burn management. The company’s working capital is negative (~-$0.32M), and free cash flow is materially negative (FCF-to-equity and FCF-to-firm are strongly negative), which is typical for pre-revenue biotech but raises solvency/timing risk if trials require additional funding. The competitive thesis appears to rely on a portfolio of investigational therapies across dermatology (PCS499 for necrobiosis lipoidica), GI disorders (PCS12852, Phase 2A), and oncology (PCS3117 in Phase 2B; PCS6422 in Phase 1B; PCS11T in diverse cancer settings). Market sentiment can swing sharply around trial updates and financing events. While the dataset includes indicators suggesting some “de-risked” approach using existing clinical evidence or rationale, the primary fundamental driver remains the probability of success across multiple clinical programs—particularly dose selection, safety/tolerability, and statistically meaningful endpoints that can lead to partnerships, larger financings, or eventual commercialization. Given the pre-commercial status, the objective investment case is best framed as a high-risk, binary-outcome opportunity. Without reliable, up-to-date segment financials (income statement/balance sheet/cash flow were not provided beyond the TTM snapshot), the most data-supported conclusion is that current financial strength and profitability are not adequate for a defensive stance; therefore risk-adjusted expectations should be conservative until clearer evidence of clinical efficacy and/or funding runway improvement emerges.

주요 강점 의 PCSA

Multi-asset pipeline spanning dermatology, GI disorders, and oncology, which diversifies clinical-stage event risk across indications
Lead program (PCS499) is in Phase 2B for necrobiosis lipoidica, offering a closer-to-value inflection point than earlier-stage assets
Oncology pipeline includes Phase 2B (PCS3117) and Phase 1B (PCS6422), providing multiple opportunities for milestone-driven re-rating
Technology/strategy positioned around leveraging existing clinical evidence and “de-risking” rationale (per company messaging), potentially improving probability of success versus purely novel mechanisms
Small-cap public-company flexibility can allow nimble trial design and rapid incorporation of data into development plans
Recent communications in the dataset/given materials indicate continued clinical activity and capital-market engagement (e.g., public offering/pricing context)

위험 요인 의 PCSA

Pre-revenue, clinical-stage nature: value depends heavily on trial outcomes, making returns highly binary and sensitive to interim/final efficacy results
Liquidity and funding risk: current ratio and quick ratio are below 1 (≈0.866) with negative working capital and strongly negative free cash flow, increasing reliance on future capital raises
Solvency/timing risk for near-term operations given negative invested capital metrics and material cash burn (typical for biotech, but still critical)
Profitability metrics and valuation ratios are not meaningful (loss-making; negative/invalid P/E and margins in the provided snapshot), limiting confidence in intrinsic valuation from earnings power
Volatility risk: small biotech stocks commonly experience large price swings around trial headlines and financing announcements (noted in provided risk-factor content)
Clinical and regulatory risk across multiple programs (patient recruitment, endpoint selection, safety signals, and FDA/EMA acceptance) can delay or terminate development
Financing dilution risk: additional equity/debt funding to sustain trials can dilute existing shareholders, especially if offered on unfavorable terms
Industry/macro risk: risk appetite for small-cap biotech and cost of capital can tighten quickly, constraining execution

시가총액 vs 매출 & 이익

이익

n/a

매출

n/a

시가총액

$5.67M

-0.4x

P/E 비율

0.0x

P/S 비율

이익 & 매출

최근 보고n/a

주당순이익(EPS)n/a

매출총이익률0.00%

순이익률0.00%

부채/자본 비율0.00

수익성 브리지(현재 vs 전년 동기)

총이익률, 영업이익률, 순이익률이 전년 대비 어떻게 바뀌었는지 보여줍니다.

매출 / 순이익 / FCF 추이(십억 달러)

성장 신호 의 PCSA

지표	현재	이전	전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다.	전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다.	신호
매출	—	—	—	—	보합
희석 EPS	—	—	—	—	보합
잉여현금흐름	—	—	—	—	보합

수익성 의 PCSA

지표	현재	이전	전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다.	전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다.	신호
순이익률	—	0.00%	—	—	보합
영업이익률	—	0.00%	—	—	보합
ROE	—	—	—	—	보합

재무 건전성 의 PCSA

지표	현재	이전	전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다.	전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다.	신호
유동비율	—	0.866	—	—	보합
당좌비율	—	0.866	—	—	보합
부채 / 자본	—	0.000	—	—	보합

가치평가 의 PCSA

지표	현재	이전	전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다.	전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다.	신호
P/E	—	-0.40x	—	—	보합
P/B	—	-16.64x	—	—	보합

PCSA Supply Chain

RELATIONS

Upstream

Elion Oncology, Inc.Aposense Ltd.TASE:APOSYuhan CorporationKRX:000100Sun Pharmaceutical Industries LimitedNSE:SUNPHARMACoNCERT Pharmaceuticals, Inc.UnconfirmedPromet Therapeutics, LLCOpus Genetics, Inc. (fka Ocuphire Pharma, Inc.)NASDAQ:IRDAkashi Therapeutics, Inc.

Downstream

Intact Therapeutics, Inc.

Proxies

Yuhan CorporationKRX:000100Sun Pharmaceutical Industries LimitedNSE:SUNPHARMAAposense Ltd.TASE:APOSOpus Genetics, Inc.NASDAQ:IRD

회사 소개개인정보 처리방침서비스 약관면책 조항종목 디렉터리ETF지수13F 보유 종목목표주가무료 도구기술 지도Slack 참여하기

Plutux는 투자자문업자가 아닙니다. 시장 데이터와 AI가 생성한 분석은 정보 제공 및 교육 목적일 뿐 투자 자문이 아닙니다. 면책 조항